Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction.

abstract：:The use of liposomal carriers and the modification of therapeutic molecules through the attachment of poly(ethylene glycol) [PEG] moieties ('pegylation') are the most common approaches for enhancing the delivery of parenteral agents. Although 'classical' liposomes (i.e. phospholipid bilayer vehicles) have been effecti...

journal_title：Clinical pharmacokinetics

authors： Harris JM,Martin NE,Modi M

更新日期：2001-01-01 00:00:00

abstract：:The half-life and metabolic clearance rate (MCR) of antipyrine and phenytoin were determined in 14 young (mean age: 28.8 +/- 8.3 (SD) years] and in 14 elderly [mean age: 83.5 +/- 7.1 (SD) years] subjects and correlated with liver volume, which was determined by ultrasonic scanning, to see if an age-dependent differenc...

journal_title：Clinical pharmacokinetics

authors： Bach B,Hansen JM,Kampmann JP,Rasmussen SN,Skovsted L

更新日期：1981-09-01 00:00:00

abstract：:20 routine patients with endogenous depression were investigated in a kinetic and 4 week treatment study. Steady-state plasma nortriptyline concentrations above 200 microgram/L were associated with a highly significant poorer therapeutic outcome. The correlations between the 24, 48 and 72 hour concentrations and stead...

journal_title：Clinical pharmacokinetics

authors： Montgomery SA,McAuley R,Montgomery DB,Braithwaite RA,Dawling S

更新日期：1979-03-01 00:00:00

abstract：:A large body of evidence suggests that not only direct anticoagulant effects but also major bleeding events and stroke prevention depend on plasma concentrations of direct oral anticoagulants (DOACs). Concomitant drugs that cause drug-drug interactions (DDIs) alter DOAC exposure by increasing or decreasing DOAC bioava...

journal_title：Clinical pharmacokinetics

authors： Foerster KI,Hermann S,Mikus G,Haefeli WE

更新日期：2020-08-01 00:00:00

abstract：:The pharmacokinetics of grepafloxacin in healthy male subjects following single oral administration of doses ranging from 200 to 1200 mg, and following repeated oral administration of 400 and 800 mg doses are reported. Plasma levels of grepafloxacin reached a peak within 2 hours (on average) following drug administrat...

journal_title：Clinical pharmacokinetics

authors： Efthymiopoulos C,Bramer SL,Maroli A

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Escitalopram is one of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is thought to act by blocking the serotonin transporter (SERT). However, its dose-SERT occupancy relationship is not well known, so it is not clear what level of SERT blockade is achieved by ...

journal_title：Clinical pharmacokinetics

authors： Kim E,Howes OD,Kim BH,Chon MW,Seo S,Turkheimer FE,Lee JS,Lee YS,Kwon JS

更新日期：2017-04-01 00:00:00

abstract：:Short-term antimanic therapy with lithium and relapse-repressive, so-called "prophylactic" long-term therapy with lithium, may present clinical problems which demand an understanding of two cardinal properties of this form of therapy--the need to individualise the dose and the recognition that successful therapy invol...

journal_title：Clinical pharmacokinetics

authors： Amdisen A

更新日期：1977-03-01 00:00:00

abstract：OBJECTIVE:To investigate the effect of concomitant administration of dairy products on the pharmacokinetics and tolerability of moxifloxacin. DESIGN:This was a single-centre, randomised, controlled, nonblinded, 2-way crossover study in healthy volunteers. PARTICIPANTS:12 healthy men (aged 25 to 46 years) were enrolle...

journal_title：Clinical pharmacokinetics

authors： Stass H,Kubitza D

更新日期：2001-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered either as crushed (in the semi-upright sitting position) or as integral (in the supine position) tablets in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percu...

journal_title：Clinical pharmacokinetics

authors： Alexopoulos D,Barampoutis N,Gkizas V,Vogiatzi C,Tsigkas G,Koutsogiannis N,Davlouros P,Hahalis G,Nylander S,Parodi G,Xanthopoulou I

更新日期：2016-03-01 00:00:00

abstract：INTRODUCTION:Renal impairment may have a significant impact on the pharmacokinetics of drugs. Ad hoc studies in subjects with renal impairment are required by the regulatory authorities to propose dose adjustments in these subjects, to find a dosing regimen able to provide a systemic exposure similar to those in subjec...

journal_title：Clinical pharmacokinetics

authors： Borella E,Poggesi I,Magni P

更新日期：2018-04-01 00:00:00

abstract：:Lignocaine is widely used as a local anaesthetic and antiarrhythmic drug. It is commonly administered to patients with acute myocardial infarction as prophylaxis for ventricular fibrillation, although its efficacy in preventing primary ventricular fibrillation is still debated. Toxicity, sometimes with serious clinica...

journal_title：Clinical pharmacokinetics

authors： Benowitz NL,Meister W

更新日期：1978-05-01 00:00:00

abstract：:Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20...

journal_title：Clinical pharmacokinetics

authors： Mahmood I,Sahajwalla C

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

更新日期：2016-12-01 00:00:00

abstract：:The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state ...

journal_title：Clinical pharmacokinetics

authors： Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

更新日期：1985-11-01 00:00:00

abstract：OBJECTIVE:To assess the differences between patients with hepatic insufficiency and healthy subjects with regard to the pharmacokinetics, cardiac safety and overall safety of ebastine and its active metabolite carebastine. DESIGN:Open-label parallel-group study. PARTICIPANTS:24 patients with varying degrees of hepati...

journal_title：Clinical pharmacokinetics

authors： Lasseter KC,Dilzer SC,Vargas R,Waldman S,Noveck RJ

更新日期：2004-01-01 00:00:00

abstract：:Few of the articles published on antibiotics and pregnancy are concerned with pharmacokinetics. It is particularly difficult to evaluate possible alterations in pharmacokinetic parameters that may be due to pregnancy. Most data available have been obtained in connection with abortion or delivery. Such data may not be ...

journal_title：Clinical pharmacokinetics

authors： Philipson A

更新日期：1979-07-01 00:00:00

abstract：:Carbamazepine is one of the most commonly prescribed antiepileptic drugs and is also used in the treatment of trigeminal neuralgia and psychiatric disorders, particularly bipolar depression. Because of its widespread and long term use, carbamazepine is frequently prescribed in combination with other drugs, leading to ...

journal_title：Clinical pharmacokinetics

authors： Spina E,Pisani F,Perucca E

更新日期：1996-09-01 00:00:00

abstract：:It has been suggested that the minimum effective serum clozapine concentration for an acceptable clinical response (threshold value) is about 400 micrograms/L. This article argues against the use of therapeutic drug monitoring (TDM) as a tool to obtain clozapine concentrations of > or = 400 micrograms/L in the individ...

journal_title：Clinical pharmacokinetics

authors： Olesen OV

更新日期：1998-06-01 00:00:00

abstract：:According to recent clinical consensus, pharmacotherapy of inflammatory bowel disease (IBD) is, or should be, personalized medicine. IBD treatment is complex, with highly different treatment classes and relatively few data on treatment strategy. Although thorough evidence-based international IBD guidelines currently e...

journal_title：Clinical pharmacokinetics

authors： Derijks LJJ,Wong DR,Hommes DW,van Bodegraven AA

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

journal_title：Clinical pharmacokinetics

authors： Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

更新日期：2005-01-01 00:00:00

abstract：:The relative bioavailability of a single oral dose of temafloxacin given with and without enteral feeding was determined in 18 healthy male volunteers in a randomised crossover study. Subjects were administered 600mg of temafloxacin orally as an intact tablet, or a crushed tablet suspended in water administered throug...

journal_title：Clinical pharmacokinetics

authors： Lubowski TJ,Nightingale CH,Sweeney K,Quintiliani R

更新日期：1992-01-01 00:00:00

abstract：:In the drug therapy of cardiac emergencies, it is necessary to rapidly achieve therapeutic drug concentrations and adjust drug dose as the patient's clinical status changes. Cardiac dysfunction is often present and may alter drug pharmacokinetics. Circulatory failure causes sympathetically mediated vasoconstriction in...

journal_title：Clinical pharmacokinetics

authors： Pentel P,Benowitz N

更新日期：1984-07-01 00:00:00

abstract：:Sulphonylureas have remained the mainstay of oral therapy for type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). They stimulate insulin release from pancreatic beta cells. Pharmacokinetic differences between the various sulphonylureas are of clinical importance in terms of the time to onset of action, timing of...

journal_title：Clinical pharmacokinetics

authors： Melander A,Donnelly R,Rydberg T

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Understanding pharmacokinetic disposition of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients ...

journal_title：Clinical pharmacokinetics

authors： Liu J,Neely M,Lipman J,Sime F,Roberts JA,Kiel PJ,Avedissian SN,Rhodes NJ,Scheetz MH

更新日期：2020-08-01 00:00:00

abstract：:The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment. Systemic exposure to the drugs or their main metabolites was determined dur...

journal_title：Clinical pharmacokinetics

authors： Lévi F,Karaboué A,Etienne-Grimaldi MC,Paintaud G,Focan C,Innominato P,Bouchahda M,Milano G,Chatelut E

更新日期：2017-02-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Numerous population pharmacokinetic (PK) models of tacrolimus in adult transplant recipients have been published to characterize tacrolimus PK and facilitate dose individualization. This study aimed to (1) investigate clinical determinants influencing tacrolimus PK, and (2) identify areas requ...

journal_title：Clinical pharmacokinetics

authors： Kirubakaran R,Stocker SL,Hennig S,Day RO,Carland JE

更新日期：2020-11-01 00:00:00

abstract：:Voriconazole is both a substrate and a potent inhibitor of cytochrome P450 (CYP) 3A. It has a high bioavailability and non-linear pharmacokinetics. We investigated the pharmacokinetics and metabolism of 50 mg and 400 mg doses of intravenous and oral voriconazole in 14 healthy volunteers. Concurrently, we determined sy...

journal_title：Clinical pharmacokinetics

authors： Hohmann N,Kocheise F,Carls A,Burhenne J,Weiss J,Haefeli WE,Mikus G

更新日期：2016-12-01 00:00:00

abstract：:The pharmacokinetics and cardiovascular effects of the calcium entry blocker nisoldipine (10 mg twice daily) were studied in 6 patients with renal failure (creatinine clearance 23 +/- 9 ml/min) and 6 healthy control subjects after a single dose and 1 week of oral administration. No significant differences in eliminati...

journal_title：Clinical pharmacokinetics

authors： van Harten J,Burggraaf J,van Brummelen P,Breimer DD

更新日期：1989-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Therapeutic hypothermia can influence the pharmacokinetics and pharmacodynamics of drugs, the discipline which is called thermopharmacology. We studied the effect of therapeutic hypothermia on the pharmacokinetics of phenobarbital in asphyxiated neonates, and the clinical efficacy and the effe...

journal_title：Clinical pharmacokinetics

authors： van den Broek MP,Groenendaal F,Toet MC,van Straaten HL,van Hasselt JG,Huitema AD,de Vries LS,Egberts AC,Rademaker CM

更新日期：2012-10-01 00:00:00

abstract：OBJECTIVE:A prospective pharmacokinetic study was performed in Caucasian patients from an intensive care unit with respiratory support to evaluate the influence of this circumstance on the pharmacokinetic behaviour of levofloxacin. PATIENTS AND METHODS:A standard dosage regimen of 500 mg/day was administered to nine C...

journal_title：Clinical pharmacokinetics

authors： Sánchez Navarro A,Colino Gandarillas CI,Alvarez Lerma F,Menacho YA,Domínguez-Gil A

更新日期：2005-01-01 00:00:00